Copyright © 2012 Patricia Muñoz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The molecular mechanisms involved in the neurodegenerative process of Parkinson’s disease remain unclear. Currently, there is a general agreement that mitochondrial dysfunction, α-synuclein aggregation, oxidative stress, neuroinflammation, and impaired protein degradation are involved in the neurodegeneration of dopaminergic neurons containing neuromelanin in Parkinson’s disease. Aminochrome has been proposed to play an essential role in the degeneration of dopaminergic neurons containing n...
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are generated primarily from endog...
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. The exact causes of ...
L-Dopa continues to be the gold drug in Parkinson's disease ( PD) treatment from 1967. The failure t...
The molecular mechanisms involved in the neurodegenerative process of Parkinson's disease remain unc...
Copyright © 2012 Maria F. Galindo et al. This is an open access article distributed under the Creati...
In 1967, L-dopa was introduced as part of the pharmacological therapy of Parkinson's disease (PD) an...
The ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP) are the two most importan...
Copyright © 2012 David Protter et al. This is an open access article distributed under the Creative ...
Artículo de publicación ISIThe molecular mechanisms causing the loss of dopaminergic neurons contai...
Parkinson's disease (PD) is a chronic neurodegenerative condition affecting more than 1% of people o...
Abstract: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. The exact ...
Copyright © 2015 Michela Zaltieri et al.This is an open access article distributed under the Creativ...
For 50 years ago was introduced L-3,4-dihydroxyphenylalanine (L-dopa) in Parkinson's disease treatme...
Aminochrome, the precursor of neuromelanin, has been pro-posed to be involved in the neurodegenerati...
Copyright © 2015 Carlos Fernández-Moriano et al. This is an open access article distributed under t...
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are generated primarily from endog...
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. The exact causes of ...
L-Dopa continues to be the gold drug in Parkinson's disease ( PD) treatment from 1967. The failure t...
The molecular mechanisms involved in the neurodegenerative process of Parkinson's disease remain unc...
Copyright © 2012 Maria F. Galindo et al. This is an open access article distributed under the Creati...
In 1967, L-dopa was introduced as part of the pharmacological therapy of Parkinson's disease (PD) an...
The ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP) are the two most importan...
Copyright © 2012 David Protter et al. This is an open access article distributed under the Creative ...
Artículo de publicación ISIThe molecular mechanisms causing the loss of dopaminergic neurons contai...
Parkinson's disease (PD) is a chronic neurodegenerative condition affecting more than 1% of people o...
Abstract: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. The exact ...
Copyright © 2015 Michela Zaltieri et al.This is an open access article distributed under the Creativ...
For 50 years ago was introduced L-3,4-dihydroxyphenylalanine (L-dopa) in Parkinson's disease treatme...
Aminochrome, the precursor of neuromelanin, has been pro-posed to be involved in the neurodegenerati...
Copyright © 2015 Carlos Fernández-Moriano et al. This is an open access article distributed under t...
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are generated primarily from endog...
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. The exact causes of ...
L-Dopa continues to be the gold drug in Parkinson's disease ( PD) treatment from 1967. The failure t...